Case Report
A Liver Transplant for Local Control in a Pediatric Patient with Metastatic TFE3-Associated Perivascular Epithelioid Cell Tumor (PEComa) to the Liver

Whayoung Lee,1 Josephine HaDuong,2 Aaron Sassoon,3 Tuan Dao,4 and Ali Nael5

1Department of Pathology, University of California Irvine Medical Center, 101 The City Drive South, Bldg. 1, Room 3003 Orange, CA 92868, USA
2Pediatric Oncology Department, Children’s Hospital of Orange County (CHOC), 1201 West La Veta Ave. Orange, CA 92868, USA
3Pathology Department, Children’s Hospital of Orange County (CHOC), 1201 West La Veta Ave. Orange, CA 92868, USA
4Radiology Department, Children’s Hospital of Orange County (CHOC), 1201 West La Veta Ave. Orange, CA 92868, USA
5Pathology Department, Children’s Hospital of Orange County (CHOC) and University of California Irvine Medical Center, 1201 West La Veta Ave. Orange, CA 92868, USA

Correspondence should be addressed to Ali Nael; anaelamzajerdi@choc.org

Received 5 May 2021; Accepted 14 September 2021; Published 5 October 2021

Academic Editor: Piero Tosi

Copyright © 2021 Whayoung Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors with widespread distribution throughout the body and unpredictable clinical behavior. Recently, a subset of these tumors has been reported to harbor Transcription Factor E3 (TFE3) gene rearrangement with distinct morphologic and immunophenotypic features. Although limited, these tumors may represent a separate entity from the conventional PEComas and may require different treatment approaches. Surgery is the main treatment option with no clear consensus on systemic therapy. Here, we present the first case of a malignant pediatric colonic TFE3-associated PEComa with isolated liver metastasis leading to liver transplantation for the local control.

1. Introduction
Perivascular epithelioid cell tumors (PEComas) are rare mesenchymal tumors composed of perivascular epithelioid cells exhibiting melanocytic and muscular differentiation. The distribution is ubiquitous throughout the body, including skin, soft tissue, bone, and visceral organs [1]. Clinical behavior ranges from benign to malignant, without a reliable predictor. Surgery remains the mainstay of treatment with no clear consensus on systemic therapy for malignant or metastatic tumors. While mostly arising sporadically, a strong association with tuberous sclerosis complex (TSC) and a high frequency of TSC1 or TSC2 inactivation mutation has been reported [2, 3]. Recently, a subset of PEComas has been found to harbor Transcription Factor E3 (TFE3) gene rearrangement, which seems to be mutually exclusive to the TSC mutation [4–7]. Although cases are limited, distinct histologic and immunophenotypic features of TFE3-associated PEComas such as alveolar architecture composed of epithelioid cells with a clear and eosinophilic cytoplasm, no significant pleomorphism, strong TFE3 immunoreactivity, and absence of smooth muscle differentiation by immunohistochemical staining suggest that these may represent a separate entity [5, 7]. Here, we report the first case of a pediatric colonic TFE3-associated PEComa with isolated distant metastasis to the liver requiring a liver transplant to control the disease.

2. Case Presentation
A sixteen-year old, otherwise, healthy female presented with 3 days of worsening abdominal pain. Abdomen/pelvic computed tomography (CT) demonstrated ileocecal intussusception, with a 5 cm mass as the lead point (Figure 1(a)). A
diagnostic laparoscopy and subsequent right hemicolectomy were performed. The polypoid tumor was confined to the cecum with negative resection margins. Microscopically, the tumor was composed of nests and sheets of uniform epithelioid cells with a pale eosinophilic cytoplasm separated by thin-walled capillary vessels (Figure 2(a)). Tumor cells with melanin pigmentation and foci of tumor necrosis were seen. Mitotic figures were up to 9 per 10 high power fields (HPF), and lymphovascular invasion was identified. Thirty-nine lymph nodes were found without metastatic disease. By immunohistochemistry, the tumor cells were positive for HMB45, Melan A, TFE3 (Figures 2(b)–2(d)), and inhibin and negative for cytokeratin, PAX8, CD117, DOG1, smooth muscle actin, desmin, S100, and neuroendocrine markers. A fluorescence in situ hybridization (FISH) study confirmed TFE3 (Xp11.23) gene rearrangement with no evidence of ASPSCR1 gene fusion. The diagnosis of localized PEComa with a high-risk malignant potential was conferred. A follow-up image at 3 months postoperation detected metastatic recurrence diffusely involving but isolated to the liver (Figure 1(b)) that was confirmed by a core biopsy. She was started on sirolimus with no response and then transitioned to gemcitabine/docetaxel with no radiographic evidence of metastatic spread beyond the liver after 6 cycles. She received a donor liver 6 months after recurrence. The explant pathology showed the same tumor with negative resection margins, less than 50% necrosis, and eight hilar lymph nodes with tumor involvement. Although regional lymph node involvement was seen, posttransplant imaging has not detected recurrence and the patient remains disease free eight months posttransplant.

3. Discussion

As PEComas have been increasingly recognized in recent years, the biggest challenge is to predict the clinical behavior of the tumor. It ranges from benign to malignant, without an absolute correlation with the site of origin or definite histologic predictors. The World Health Organization (WHO) proposes the use of different histologic parameters (adopted from Folpe et al. [8]) for the identification of PEComas with a potentially aggressive clinical behavior, mainly applying to the PEComas in the gynecologic tract [6]. Those include size larger than 5 cm, infiltrative growth pattern, high nuclear grade and cellularity, mitoses greater than 1 per 50 HPF, necrosis, and vascular invasion [6]. A subsequent study by Bleeker et al. looking at 234 PEComas from different organs used the same WHO/Folpe parameters to divide these tumors into three categories: benign (<2 high-risk features and size < 5 cm), uncertain malignant potential (size ≥ 5 cm with no other high-risk features or nuclear pleomorphism alone), or malignant (2 or more high-risk features) [1]. Currently, the Folpe criteria are used for limited prediction of the tumor behavior, as only about half of the patients diagnosed as having “malignant” PEComa recur following resection [1, 8].

Recently, a subset of PEComas has been reported to harbor TFE3 gene rearrangement, a member of the MiT family of transcription factors. TFE3-associated PEComas have unique histologic and immunophenotypic features, including alveolar architecture composed of epithelioid cells with a clear and eosinophilic cytoplasm, no significant pleomorphism, strong TFE3 immunoreactivity, and absence of smooth muscle differentiation by immunohistochemical staining [5, 7, 9].

Approximately 50 cases of PEComas arising from the gastrointestinal (GI) tract have been reported in the literature. Like PEComas from other areas, GI PEComas exhibit a spectrum of biologic behavior from benign to malignant with no clear consensus on how to predict malignant behavior or optimal systemic therapy. Doyle et al. studied 35 GI PEComas and reported that approximately 30% of cases
exhibited malignant behavior with local recurrence, distant metastases, or disease-related death [2]. Marked atypia, diffuse pleomorphism, and mitoses ≥ 2/10 HPF were significantly associated with the malignant behavior [2]. Unlike renal PEComas, GI PEComas are less likely associated with TSC mutations [4, 5].

Only 13 pediatric GI PEComas cases have been reported, ranging from 6 to 17 years of age with a female predilection, and the most common location is the distal colon (Table 1) [5, 10–21]. Interestingly, 2 cases occurred in patients with history of neuroblastoma, and no association with TSC mutations has been observed [12, 17]. TFE3 immunostaining was performed in four cases, and they were all positive. However, FISH confirmation was performed in two of them. Two cases presented with the regional lymph node involvement at the time of surgery (only one received chemotherapy). As opposed to GI PEComas in adults with 30% exhibiting malignant behavior, no disease-related death, distance metastasis, or local recurrence has been reported in the pediatric cases (except our case) with an average follow-up of 37 months, including the two cases with regional lymph node involvement at the time of diagnosis [5, 15–17].

While optimal treatment for PEComa has not been established, surgical resection with clear margin appears to be the mainstay of the therapy. Most patients who have progressive disease with distant metastases or lymph node involvement receive adjuvant treatment but the benefit has not yet been determined [1]. The fact that germline or sporadic TSC mutation results in subsequent activation of the mammalian target of rapamycin (mTOR) pathway supports the use of mTOR inhibitors (sirolimus) for targeted therapy in patients with locally aggressive or metastatic disease [2], which have been promising in some studies [1, 3, 6, 22]. As there is no TSC gene involvement in TFE3-associated PEComas, it is unclear if these patients would respond to mTOR inhibitors. However, targeting the MIT family of

Figure 2: (a) The histologic features of the tumor which were composed of nests and sheets of epithelioid cells with frequent melanin pigmentation separated by thin-walled capillary vessels (predominant alveolar architecture) (hematoxylin and eosin (H&E) staining, magnification ×200). Tumor cells demonstrate immunohistochemical reactivity for (b) TFE3, (c) HMB45, and (d) Melan A (b–d, magnification ×200).
transcription factors where the TFE3 gene resides may aid the treatment of this distinct entity. Other agents exhibiting activity in PEComas include antiangiogenics and gemcitabine- or anthracycline-based chemotherapy regimens [22].

Given that PEComas cannot be successfully treated without surgery, our patient was considered for liver transplantation as definitive resection after demonstrating no extrahepatic disease for six months after recurrence. This represents the first case to our knowledge of a patient with a diagnosis of PEComa receiving a transplant, a resection option that may be considered in pediatric patients with the disease isolated to one organ.

Although it is a rare tumor, PEComa should be considered in the differential diagnosis of mesenchymal tumors, particularly of the GI tract, and TFE3 status should be evaluated in all cases, as TFE3-associated PEComas may represent as a distinct entity from conventional PEComas and may require different therapeutic decisions.

**Conflicts of Interest**

The authors declare that they have no conflict of interest.

**Acknowledgments**

This work was supported by our department using our faculty accounts to pay for any additional expenses.

---

**Table 1: Graph demonstrating results.**

| Age (yr.)/sex | Location            | Size (cm) | Margin status | Lymph node | Nuclear atypia | Mitosis/10 HPF | Prognosisa | TFE3 IHCb | TFE3 FISHc | Reference |
|---------------|---------------------|-----------|---------------|------------|---------------|---------------|-------------|-----------|-----------|-----------|
| 6/F           | Appendix            | 1.3       | NA            | NA         | Yes           | 0             | NA          | NA        | NA        | [10]      |
| 9/F           | Rectum              | 3         | Neg           | Neg        | No            | Rare          | 14 MO NED   | NA        | NA        | [11]      |
| 12/M          | Duodenum            | 3.5       | Neg           | Neg        | No            | Low           | 24 MO NED   | NA        | NA        | [12]      |
| 16/F          | Transverse colon    | 2         | NA            | Neg        | NA            | 0             | 24 MO NED   | NA        | NA        | [13]      |
| 11/M          | Sigmoid colon       | 1.2       | Neg           | Pos        | No            | Occasional    | 5 MO NED    | NA        | NA        | [14]      |
| 11/M          | Descending/sigmoid colon | 3.5 | Neg           | NA         | NA            | Infrequent    | NA          | Pos       | NA        | [15]      |
| 16/F          | Transverse colon    | 1.8       | NA            | Neg        | NA            | NA            | 41 MO NED   | Pos       | NA        | [16]      |
| 14/F          | Sigmoid colon       | 6.4       | Neg           | NA         | NA            | Rare          | NA          | Pos       | Pos       | [17]      |
| 15/F          | Rectum              | 3.7       | Neg           | Pos        | No            | 2             | 9 MO NED    | NA        | NA        | [18]      |
| 16/F          | Colon               | NA        | NA            | NA         | NA            | NA            | NA          | Pos       | Pos       | [5]       |
| 17/F          | Sigmoid colon       | 6         | Neg           | NA         | No            | NA            | 180 MO NED  | NA        | NA        | [19]      |
| 7/M           | Ascending colon     | 4         | Neg           | Neg        | No            | Low           | 26 MO NED   | NA        | NA        | [20]      |
| 17/M          | Rectum              | 3         | Neg           | Neg        | <1            | 10 MO NED     | NA          | NA        | NA        | [21]      |
| 16/F          | Ascending colon     | 5         | Neg           | Neg        | No            | Up to 9       | Liver met. after 3 MO | Pos | Pos | Our case |

Abbreviation: F: female; FISH: fluorescent in situ hybridization; HPF: high power fields; IHC: immunohistochemistry; M: male; Met: metastasis; MO: month; NA: no data available; Neg: negative; NED: no evidence of disease; Pos: positive; Ref.: reference; yr.: year(s). aFollow-up since the first diagnosis. bTFE3 expression by immunohistochemistry. cGene rearrangement involving TFE3 (Xp11.23) by FISH.

---

**References**

[1] J. S. Bleeker, J. F. Quevedo, and A. L. Folpe, “‘Malignant’ Perivascular Epithelioid Cell Neoplasm: Risk Stratification and Treatment Strategies,” Sarcoma, vol. 2012, Article ID 541626, 12 pages, 2012.

[2] L. A. Doyle, J. L. Hornick, and C. D. Fletcher, "PEComa of the gastrointestinal Tract," The American Journal of Surgical Pathology, vol. 37, no. 12, pp. 1769–1782, 2013.

[3] H. Kenerson, A. L. Folpe, T. K. Takayama, and R. S. Yeung, "Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms," Human Pathology, vol. 38, no. 9, pp. 1361–1371, 2007.

[4] Z. Chen, S. Han, J. Wu et al., "A systematic review: perivascular epithelioid cell tumor of gastrointestinal tract," Medicine (Baltimore), vol. 95, no. 28, article e3890, 2016.

[5] P. Argani, S. Aulmann, P. B. Illei et al., "A distinctive subset of PEComas harbors TFE3 gene fusions," The American Journal of Surgical Pathology, vol. 34, no. 10, pp. 1395–1406, 2010.

[6] A. M. Acosta and B. P. Adley, "Predicting the behavior of perivascular epithelioid cell tumors of the uterine corpus," Archives of Pathology & Laboratory Medicine, vol. 141, no. 3, pp. 463–469, 2017.

[7] I. Malinowska, D. J. Kwiatkowski, S. Weiss, G. Martignoni, G. Netto, and P. Argani, "Perivascular epithelioid cell tumors (PEComas) harboring TFE3 gene rearrangements lack the TSC2 alterations characteristic of conventional PEComas: further evidence for a biological distinction," The American Journal of Surgical Pathology, vol. 36, no. 5, pp. 783–784, 2012.
[8] A. L. Folpe, T. Mentzel, H. A. Lehr, C. Fisher, B. L. Balzer, and S. W. Weiss, “Perivascular epithelioid cell neoplasms of soft tissue and gynecologic Origin,” The American Journal of Surgical Pathology, vol. 29, no. 12, pp. 1558–1575, 2005.

[9] M. Lee, K. J. Cho, C. Yu et al., “Perivascular epithelioid cell tumor of the sigmoid colon with transcription factor E3 expression,” Annals of Diagnostic Pathology, vol. 16, no. 4, pp. 306–311, 2011.

[10] M. L. Prasad, J. P. Keating, H. H. Teoh et al., “Pleomorphic angiomyolipoma of digestive tract: a heretofore unrecognized entity,” International Journal of Surgical Pathology, vol. 8, no. 1, pp. 67–72, 2000.

[11] H. D. Tazelaar, K. P. Batts, and J. R. Srigley, “Primary extrapulmonary sugar tumor (PEST): a report of four cases,” Modern Pathology, vol. 14, no. 6, pp. 615–622, 2001.

[12] T. Mhanna, D. Ranchere-Vince, V. Hervieu, D. Tardieu, J. Y. Scoazec, and C. Partensky, “Clear cell myomelanocytic tumor (PEComa) of the duodenum in a child with a history of neuroblastoma,” Archives of Pathology & Laboratory Medicine, vol. 129, no. 11, pp. 1484–1486, 2005.

[13] J. H. Baek, M. Gi Chung, D. Hae Jung, and J. H. Oh, “Perivascular epithelioid cell tumor (PEComa) in the transverse colon of an adolescent: a case report,” Tumori, vol. 93, no. 1, pp. 106–108, 2007.

[14] U. Pisharody, R. D. Craver, R. F. Brown, R. Gardner, and E. Schmidt-Sommerfeld, “Metastatic perivascular epithelioid cell tumor of the colon in a child,” Journal of Pediatric Gastroenterology and Nutrition, vol. 46, no. 5, pp. 598–601, 2008.

[15] A. Righi, K. Dimosthenous, and J. Rosai, “PEComa: another member of the MiT tumor family?,” International Journal of Surgical Pathology, vol. 16, no. 1, pp. 16–20, 2008.

[16] H. Y. Cho, D. H. Chung, H. Khurana, Q. J. Zhai, and J. Y. Ro, “The role of TFE3 in PEComa,” Histopathology, vol. 53, no. 2, pp. 236–249, 2008.

[17] M. Tanaka, K. Kato, K. Gomi et al., “Perivascular epithelioid cell tumor with SFPQ/PSF-TFE3 gene fusion in a patient with advanced neuroblastoma,” The American Journal of Surgical Pathology, vol. 33, no. 9, pp. 1416–1420, 2009.

[18] P. Ryan, V. H. Nguyen, S. Gholoum et al., “Polypoid PEComa in the rectum of a 15-year-old Girl,” The American Journal of Surgical Pathology, vol. 33, no. 3, pp. 475–482, 2009.

[19] H. J. Freeman and D. L. Webber, “Perivascular epithelioid cell neoplasm of the colon,” World journal of gastrointestinal oncology, vol. 2, no. 4, pp. 205–208, 2010.

[20] S. J. Park, D. K. Han, H. J. Baek et al., “Perivascular epithelioid cell tumor (PEComa) of the ascending colon: the implication of IFN-α2b treatment,” Korean Journal of Pediatrics, vol. 53, no. 11, pp. 975–978, 2010.

[21] S. Im, C. Yoo, J. H. Jung, H. J. Choi, J. Yoo, and C. S. Kang, “Primary perivascular epithelioid cell tumor in the rectum: a case report and review of the literature,” Pathology, Research and Practice, vol. 209, no. 4, pp. 244–248, 2013.

[22] R. Sanfilippo, R. L. Jones, J. Y. Blay et al., “Role of chemotherapy, VEGFR inhibitors, and mTOR inhibitors in advanced perivascular epithelioid cell tumors (PEComas),” Clinical Cancer Research, vol. 25, no. 17, pp. 5295–5300, 2019.